For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group. Exclusions before Randomisation Exclusions after Randomisation Sample Size Slippages in Randomised Trials: Exclusions and the Lost and Wayward
暂无分享,去创建一个
[1] Mark C. Wilson. Evidence-Based Medicine: How to Practice and Teach EBM , 2001, ACP Journal Club.
[2] M. Pike,et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. , 1977, British Journal of Cancer.
[3] Kenneth F Schulz,et al. Allocation concealment in randomised trials: defending against deciphering , 2002, The Lancet.
[4] S. Satya‐Murti. Evidence-based Medicine: How to Practice and Teach EBM , 1997 .
[5] P. Armitage,et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design. , 1976, British Journal of Cancer.
[6] J H Ellenberg,et al. Analysis of clinical trials by treatment actually received: is it really an option? , 1991, Statistics in medicine.
[7] U. Tamoufé,et al. Effect of nonoxynol-9 gel on urogenital gonorrhea and chlamydial infection: a randomized controlled trial. , 2002, JAMA.
[8] C. Meinert,et al. Content of reports on clinical trials: a critical review. , 1984, Controlled clinical trials.
[9] D. Moher,et al. The Revised CONSORT Statement for Reporting Randomized Trials: Explanation and Elaboration , 2001, Annals of Internal Medicine.
[10] D. Machin,et al. Intention to treat--who should use ITT? , 1993, British Journal of Cancer.
[11] Frederick Mosteller,et al. Reporting on methods in clinical trials. , 1982, The New England journal of medicine.
[12] D. Moher,et al. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials , 2001, The Lancet.
[13] P. Meier. Anturane reinfarction trial. , 1981, New England Journal of Medicine.
[14] S. Hollis,et al. What is meant by intention to treat analysis? Survey of published randomised controlled trials , 1999, BMJ.
[15] K. Schulz,et al. An overview of clinical research: the lay of the land , 2002, The Lancet.
[16] C. Bulpitt,et al. Clinical Trials—Issues and Approaches , 1984 .
[17] R. J. Hayes,et al. Blinding and exclusions after allocation in randomised controlled trials: survey of published parallel group trials in obstetrics and gynaecology , 1996, BMJ.
[18] Sulfinpyrazone in the prevention of sudden death after myocardial infarction. , 1980, The New England journal of medicine.
[19] J M Lachin,et al. Statistical considerations in the intent-to-treat principle. , 2000, Controlled clinical trials.
[20] G. Pledger,et al. The FDA's critique of the anturane reinfarction trial. , 1980, The New England journal of medicine.
[21] Kenneth F Schulz,et al. Generation of allocation sequences in randomised trials: chance, not choice , 2002, The Lancet.
[22] T. Louis,et al. Clinical trials : issues and approaches , 1984 .